WO2020221184A1 - Composition pharmaceutique ayant pour effet de réduire l'acide urique - Google Patents

Composition pharmaceutique ayant pour effet de réduire l'acide urique Download PDF

Info

Publication number
WO2020221184A1
WO2020221184A1 PCT/CN2020/087128 CN2020087128W WO2020221184A1 WO 2020221184 A1 WO2020221184 A1 WO 2020221184A1 CN 2020087128 W CN2020087128 W CN 2020087128W WO 2020221184 A1 WO2020221184 A1 WO 2020221184A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
weight
pharmaceutical composition
inulin
citric acid
Prior art date
Application number
PCT/CN2020/087128
Other languages
English (en)
Chinese (zh)
Inventor
狄志鸿
张昌娟
Original Assignee
杭州泽健医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 杭州泽健医药科技有限公司 filed Critical 杭州泽健医药科技有限公司
Publication of WO2020221184A1 publication Critical patent/WO2020221184A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention belongs to the technical field of biomedicine, and specifically contains a pharmaceutical composition with uric acid lowering and anti-fatigue effects.
  • the essential cause of gout is the increase in the level of uric acid in the body, which causes the deposition of urate in the joints and kidneys.
  • the main causes of gout include but are not limited to: (1) dietary reasons. After eating too much meat and seafood, and drinking too much beer, the body's uric acid level increases, which may cause urate deposition; (2) Obesity. The consequence of obesity is the increase of uric acid in the body, and the kidneys cannot completely remove the excess uric acid; (3) Taking certain drugs. These drugs can increase the level of uric acid in the body; (4) Family history. If your family member suffers from gout, the probability of your illness will also increase greatly.
  • Gout is a common and complex type of arthritis, which can be affected by all ages.
  • the incidence rate of men is higher than that of women.
  • Gout patients often experience sudden joint pain at night, the onset is acute, severe pain, edema, redness, and inflammation appear in the joints. The pain is slowly reduced until it disappears, lasting several days or weeks. When the pain occurs, the patient wakes up in the middle of the night while sleeping.
  • Some patients describe the pain as similar to the burning of the big toe.
  • the most common joint is the big toe (medical term: first metatarsal), but the joints that are affected are not limited to this, and are also common in hand joints, knees, elbows, etc.
  • the affected joints will eventually become red, swollen and inflamed. After the edema, the tissues will become soft and movement will be restricted, which will eventually affect daily life. Therefore, research on new products that can reduce uric acid has important clinical significance.
  • the applicant obtained a new pharmaceutical composition after many creative researches, which is prepared from inulin, sodium citrate, potassium citrate and citric acid.
  • the research shows that the present invention
  • the composition has the pharmacological effect of lowering uric acid, which further illustrates that the composition of the present invention can be used for gout patients.
  • the special medical food mentioned in the present invention means that it must be consumed alone or in combination with other foods under the guidance of a doctor or clinical nutritionist. It refers to a formula food specially processed and formulated to meet the special needs of people with eating restrictions, digestion and absorption disorders, metabolic disorders or specific disease states for nutrients or diet. Special medical foods are not medicines, but they are not ordinary foods eaten by normal people. They are formula foods specially developed and produced after extensive medical research by clinicians and nutritionists and based on scientific objective facts. When the target population cannot eat ordinary meals or cannot meet their nutritional needs with daily meals, formula foods for special medical purposes can be used as a way of nutritional supplementation to play a nutritional support role. The food cannot replace the therapeutic effect of drugs, and the product cannot claim the preventive and therapeutic functions of diseases.
  • the inulin in the present invention refers to inulin or natural fructan, which uses Jerusalem artichoke (Jerusalem artichoke) rhizome or chicory as raw material to remove protein, gum, crude fiber and minerals, and is extracted with water and ion exchanged. , Membrane filtration, spray drying and other production processes to obtain inulin.
  • the present invention is achieved through the following technical solutions.
  • Said pharmaceutical composition comprises 15-20 parts by weight of inulin, 10-15 parts by weight of sodium citrate, 10-15 parts by weight of potassium citrate and 1-5 parts by weight of citric acid.
  • Said pharmaceutical composition comprises 18 parts by weight of inulin, 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and 4 parts by weight of citric acid.
  • the pharmaceutical composition is applied in the preparation of special medical food for lowering uric acid.
  • a pharmaceutical composition for treating gout which is prepared from the following raw materials: 15-20 parts by weight of inulin, 10-15 parts by weight of sodium citrate, 10-15 parts by weight of potassium citrate, and citric acid 1-5 parts by weight; the preferred pharmaceutical composition is prepared from the following raw materials: 18 parts by weight of inulin, 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and 4 parts by weight of citric acid.
  • a pharmaceutical composition with the effect of lowering uric acid which is prepared from the following raw materials: 15-20 parts by weight of inulin, 10-15 parts by weight of sodium citrate, 10-15 parts by weight of potassium citrate and lemon The acid is 1-5 parts by weight; the preferred pharmaceutical composition is prepared from the following raw materials: 18 parts by weight of inulin, 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and 4 parts by weight of citric acid.
  • the inulin in the present invention refers to inulin or natural fructan, which uses Jerusalem artichoke (Jerusalem artichoke) rhizome or chicory as raw material to remove protein, gum, crude fiber and minerals, and is extracted with water and ion exchanged. , Membrane filtration, spray drying and other production processes to obtain inulin.
  • the inulin of the present invention has the following pharmacological effects: 1. Control blood lipids; 2. Lower blood sugar; 3. Promote the absorption of minerals; 4. Adjust the intestinal microflora, improve intestinal health, and prevent constipation; 5. . Inhibit the production of toxic fermentation products, protect the liver, and prevent colon cancer; 6. Prevent constipation and treat obesity. Dietary fiber reduces the residence time of food in the gastrointestinal tract and increases the amount of feces to effectively treat constipation. Its weight loss effect is to increase the viscosity of the contents and reduce the speed of food from the stomach to the small intestine, thereby reducing hunger and reducing food intake. 7. Inulin contains a small amount of 2-9 oligofructose.
  • inulin can increase the expression of neurotrophic factors in brain nerve cells, and has a good protective effect on corticosterone-induced neuronal damage. Antidepressant effect. After the composition of inulin and citric acid, sodium citrate and potassium citrate three substances, by regulating intestinal function, etc., thereby promoting the excretion of intestinal uric acid, it has a good effect of lowering uric acid.
  • the pharmaceutical composition of the present invention can be prepared into oral solid preparations, or can be prepared into granules by adding other raw and auxiliary materials.
  • the pharmaceutical composition of the present invention can also be prepared by adding one or more of sorbitol, isomaltulose (palatinose, sucrose), nutritional fortifier premix, and sucralose Into composite powder.
  • the nutritional supplement premix includes the following components by weight: 130-140 parts of taurine, 220-230 parts of vitamin C, 10-20 parts of vitamin E, 0.5-1 parts of ⁇ -carotene, vitamin B 2 2- 3 parts vitamin B 6 1-2 parts, 5-10 parts of pantothenic acid, folic acid, 0.05 to 2 parts.
  • Preferred dietary supplement premix parts by weight of component comprising: 140 parts of taurine, 225 parts of vitamin C, vitamin E 18 parts, 0.6 parts of [beta] -carotene, vitamin B 2 2.2 parts of Vitamin B 6 1.81 parts , 8 parts of pantothenic acid, 0.06 parts of folic acid.
  • the sources of the raw and auxiliary materials of the present invention are shown in Table 1.
  • the present invention is based on inulin, supplemented by sodium citrate, potassium citrate and citric acid. It is used for gout patients and it is used under the guidance of clinicians or nutritionists, rather than ordinary food; On the basis of inulin, sodium citrate, potassium citrate and citric acid, you can also add sorbitol, isomaltulose (palatinose, sucrose), nutritional fortifier premix, three One or more of sucralose.
  • the following experiments of the present invention are conclusive experiments by research and development personnel based on the technical solutions to be protected by the present invention on the basis of multiple creative experiments.
  • the quantitative experiments in the following examples are all set to three repeated experiments, and the data is the average value of the three repeated experiments or the average ⁇ standard deviation.
  • test group
  • Test group 1 inulin
  • Test group 2 Inulin 1.8g, sodium citrate 2.6g;
  • Test group 3 Inulin 1.8g, potassium citrate 2.6g;
  • Test group 4 Inulin 1.8g, sodium malate 1.73g;
  • Test group 5 inulin 1.8g, sodium bicarbonate 0.74g;
  • Test 7 inulin 1.8g, potassium citrate 1.5g, and citric acid 1.5g.
  • Test 8 group inulin 1.8g, potassium citrate 1.4g, sodium citrate 1.2g and citric acid 0.4g.
  • Test method Kunming mice, male, weighing 18-22g, randomly grouped, blank control group, model group, test group, 10 mice in each group, except for mice in the blank group, the other groups are given potassium oxazinate every morning (100mg/kg) model, the present group was given 4g/kg of raw material every afternoon, and the model group was given the same volume of distilled water in the afternoon. Each group was administered once a day for a total of 30 days, and relevant indicators were tested on 30 days during the administration period. Index detection: Fasting for 12 hours (cannot help water) before the start of the formal experiment, and taking 1 mL of blood from the orbit before administration.
  • centrifuge 4000r/min, 15min to separate the serum and store it at -20°C for standby. Used to detect the serum UA level before the experiment. On the 30th day after the administration, the blood was collected by the same method, except for the UA level after 30 days.
  • Test group 1 Inulin 1.8g, potassium citrate 1.4g, sodium citrate 1.2g and citric acid 0.4g.
  • Test group 2 Inulin 1.8g, potassium citrate 1.4g, sodium citrate 1.2g and citric acid 0.6g.
  • Test group 4 Inulin 1.8g, potassium citrate 1.4g, sodium citrate 1.2g and citric acid 1.0g.
  • Test method same as test 1.
  • Sorbitol 3000g inulin 1500g, isomaltulose 1000g, potassium citrate 1000g, sodium citrate 1000g, citric acid 100g, nutrition enhancer premix 50g, sucralose 10g.
  • the above-mentioned raw materials are mixed completely.
  • the above-mentioned raw materials are mixed completely.
  • the above raw materials are mixed together.
  • the ratio between fortifier premix as a raw material 140 parts of taurine, 225 parts of vitamin C, vitamin E 18 parts, 0.6 parts of [beta] -carotene, vitamin B 2 2.2 parts of Vitamin B 6 1.81 Parts, 8 parts of pantothenic acid, 0.06 parts of folic acid.
  • the inulin in the present invention refers to inulin or natural fructan, which uses Jerusalem artichoke (Jerusalem artichoke) rhizome or chicory as raw material to remove protein, gum, crude fiber and minerals, and is extracted with water and ion exchanged. , Membrane filtration, spray drying and other production processes to obtain inulin.
  • the pharmaceutical composition of the present invention can be prepared into oral solid preparations, or can be prepared into granules by adding other raw and auxiliary materials.
  • composition of the present invention can be used alone to treat or prevent the onset of gout, or it can be combined with drugs for the treatment of gout, such as febuxostat, colchicine, and allopurin. Alcohol, benzbromarone and other drugs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une composition pharmaceutique ayant pour effet de réduire l'acide urique. La composition pharmaceutique est constituée d'inuline, de citrate de sodium, de citrate de potassium et d'acide citrique et peut être utilisée pour des patients atteints de goutte.
PCT/CN2020/087128 2019-04-28 2020-04-27 Composition pharmaceutique ayant pour effet de réduire l'acide urique WO2020221184A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910349869.XA CN110051002A (zh) 2019-04-28 2019-04-28 一种具有降尿酸作用的药物组合物
CN201910349869.X 2019-04-28

Publications (1)

Publication Number Publication Date
WO2020221184A1 true WO2020221184A1 (fr) 2020-11-05

Family

ID=67321315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/087128 WO2020221184A1 (fr) 2019-04-28 2020-04-27 Composition pharmaceutique ayant pour effet de réduire l'acide urique

Country Status (2)

Country Link
CN (1) CN110051002A (fr)
WO (1) WO2020221184A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110051002A (zh) * 2019-04-28 2019-07-26 杭州泽健医药科技有限公司 一种具有降尿酸作用的药物组合物
CN110651862A (zh) * 2019-11-21 2020-01-07 李海齐 一种能够促进喝茶后降低尿酸的口服固体饮料及其制备方法
CN113439846A (zh) * 2021-05-26 2021-09-28 石药集团中诺药业（泰州）有限公司 一种用于高尿酸和痛风人群的营养素组合物配方和保健食品

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557352A (zh) * 2004-01-19 2004-12-29 北京中医药大学 菊苣水提取物的新用途
CN101006996A (zh) * 2006-01-25 2007-08-01 盛骝吾 一种治疗泌尿系统结石及高尿酸血症的药物及其制备方法
CN102028703A (zh) * 2009-12-03 2011-04-27 张冰 菊粉的新用途
CN105380962A (zh) * 2015-12-11 2016-03-09 汤臣倍健股份有限公司 一种降尿酸组合物及其制剂
CN105395577A (zh) * 2015-12-11 2016-03-16 汤臣倍健股份有限公司 一种降尿酸组合物及其制剂
CN107594520A (zh) * 2017-09-20 2018-01-19 湖南慧泽生物医药科技有限公司 一种供痛风患者食用的配方食品
CN109122859A (zh) * 2018-11-01 2019-01-04 威海健康生生物科技有限公司 降尿酸组合物及其制备方法与应用
CN110038119A (zh) * 2019-04-28 2019-07-23 杭州泽健医药科技有限公司 一种具有降尿酸和抗疲劳作用的药物组合物
CN110051002A (zh) * 2019-04-28 2019-07-26 杭州泽健医药科技有限公司 一种具有降尿酸作用的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108404019A (zh) * 2018-04-27 2018-08-17 韩世忠 复方菊苣根调节嘌呤代谢紊乱的固体制品及其制备方法
CN109430667A (zh) * 2018-10-19 2019-03-08 张东祥 一种具有降尿酸作用的组合物及固体饮料
CN109511984A (zh) * 2019-01-09 2019-03-26 丁强 一种以芹菜籽、柠檬酸钾等为主要原料制备的缓解痛风的特膳食品

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557352A (zh) * 2004-01-19 2004-12-29 北京中医药大学 菊苣水提取物的新用途
CN101006996A (zh) * 2006-01-25 2007-08-01 盛骝吾 一种治疗泌尿系统结石及高尿酸血症的药物及其制备方法
CN102028703A (zh) * 2009-12-03 2011-04-27 张冰 菊粉的新用途
CN105380962A (zh) * 2015-12-11 2016-03-09 汤臣倍健股份有限公司 一种降尿酸组合物及其制剂
CN105395577A (zh) * 2015-12-11 2016-03-16 汤臣倍健股份有限公司 一种降尿酸组合物及其制剂
CN107594520A (zh) * 2017-09-20 2018-01-19 湖南慧泽生物医药科技有限公司 一种供痛风患者食用的配方食品
CN109122859A (zh) * 2018-11-01 2019-01-04 威海健康生生物科技有限公司 降尿酸组合物及其制备方法与应用
CN110038119A (zh) * 2019-04-28 2019-07-23 杭州泽健医药科技有限公司 一种具有降尿酸和抗疲劳作用的药物组合物
CN110051002A (zh) * 2019-04-28 2019-07-26 杭州泽健医药科技有限公司 一种具有降尿酸作用的药物组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIANG, GUIYUN, YAO, LIXIN: "Modern treatment and preventive rules of gout", CHINESE JOURNAL OF CLINICAL REHABILITATION, vol. 10, no. 44, 25 November 2006 (2006-11-25), DOI: 20200710102712Y *
LIANG, XIAOYU; ZHANG, XINQUAN; JI, YANG: "Non-official translation: Research Progress on Chicory Function and Product Development", HEILONGJIANG ANIMAL SCIENCE AND VETERINARY MEDICINE, no. 6, 15 June 2012 (2012-06-15), DOI: 20200710103242Y *
SUN, LU: "Non-official translation: Gout Treatment and Evaluation of Drug Interactions", EVALUATION AND ANALYSIS OF DRUG-USE IN HOSPITAL OF CHINA, vol. 8, no. 8, 31 August 2008 (2008-08-31), DOI: 20200710102921Y *
WANG, JIE YING: "Non-official translation: Gouty arthritis", CHINESE JOURNAL OF CLINICIANS, vol. 37, no. 1,, 31 January 2009 (2009-01-31), DOI: 20200710103121Y *

Also Published As

Publication number Publication date
CN110051002A (zh) 2019-07-26

Similar Documents

Publication Publication Date Title
CN103238897B (zh) 一种适用于糖尿病人的复合植物固体饮料
Bauernfeind The safe use of vitamin A: a report of the International Vitamin A Consultative Group (IVACG)
WO2020221184A1 (fr) Composition pharmaceutique ayant pour effet de réduire l'acide urique
WO2020221192A1 (fr) Composition pharmaceutique ayant des effets d'abaissement de l'acide urique et anti-fatigue
CN107183705A (zh) 一种润肠通便改善便秘的功能性食品
JP2022036990A (ja) 腸の健康を促す組成物
CN111588042A (zh) 一种辅助降低尿酸和控制痛风的膳食营养调理食品
CN109820905A (zh) 一种治疗失眠的药物组合物及其应用
JP2007277128A (ja) 生活習慣病の予防・改善方法及び予防・改善剤
McRorie Jr et al. Psyllium: The gel-forming nonfermented isolated fiber that delivers multiple fiber-related health benefits
WO2017191856A1 (fr) Effet antidiabétique du gypénoside 75
CN1917868B (zh) 包含l-丝氨酸、l-异亮氨酸、叶酸和痕量元素的用于治疗银屑病的组合物
KR100455222B1 (ko) 다이어트 인삼복합제품 및 그 제조방법
JPH11130686A (ja) 肥満症の予防、治療法および抗肥満剤
Navaro et al. Functional foods in fad diets: a review.
AU2015396019A1 (en) Composition and uses thereof
US20220047658A1 (en) Tcm addition and subtraction prescription used prevention/treatment of metabolic syndrome and complications
CN108524599A (zh) 一种中药组合物在制备治疗肠炎的药物中的用途
JP2004000171A (ja) マカを含有した機能性食品
CN112457423B (zh) 一种具有改善胰岛素抵抗作用的天然提取复合多糖及应用
CN116268414A (zh) 一种改善胃肠道功能、防治便秘的组合物及其用途
CN107753716B (zh) 一种基于多靶点干预治疗慢性荨麻疹的活性组合物及其制备方法
US20220062312A1 (en) Oral composition comprising b-escin and the use thereof
JP2001302526A (ja) カルシウム吸収促進剤
CN105431143A (zh) 使用对茴香醛的组合物和方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20799403

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20799403

Country of ref document: EP

Kind code of ref document: A1